Why Novo Nordisk Stock Just Crashed

Core Viewpoint - Novo Nordisk's stock has dropped significantly following the clinical trial results of its CagriSema drug, which showed a 23% weight loss after 84 weeks, but underperformed compared to Eli Lilly's drug, which achieved a 25.5% weight loss [1][3][4]. Group 1: Clinical Trial Results - The clinical trial for CagriSema involved 809 participants suffering from obesity and at least one comorbidity [3]. - Participants using CagriSema lost an average of 23% of their body weight, starting from an average weight of 114.2 kg [3]. - In comparison, those taking Eli Lilly's GLP-1 drug lost an average of 25.5% of their body weight [3]. Group 2: Market Reaction - Following the trial results, Novo Nordisk's stock fell by 14.8% as of 10:10 a.m. ET [1]. - Investors were disappointed because the trial did not demonstrate that CagriSema could outperform a 15 mg dose of tirzepatide, the active ingredient in Eli Lilly's Zepbound and Mounjaro [2][4]. Group 3: Future Outlook - Novo Nordisk expressed satisfaction with the 23% weight loss and plans to conduct a higher-dose trial for CagriSema [4]. - The company had previously forecasted a sales and earnings decline of 5% to 13% in 2026, and the recent trial results may delay any potential recovery [5].